Search Results - "Dovholuk, A"

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
  2. 2

    A phase Ib trial of ARQ 501, a selective checkpoint activator, in combination with docetaxel in patients with advanced solid tumors by Li, C., Nemunaitis, J., Senzer, N., Edelman, G., Glasner, S., Dombal, G., Dovholuk, A., Cunningham, C.

    Published in Journal of clinical oncology (20-06-2006)
    “…Abstract only 13053 Background: ARQ 501 is a DNA damage checkpoint activator. It directly activates DNA damage response pathways without inducing primary DNA…”
    Get full text
    Journal Article
  3. 3

    Phase 1 study of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose by Garcia, A., Rosen, L., Cunningham, C. C., Nemunaitis, J., Li, C., Rulewski, N., Dovholuk, A., Savage, R., Chan, T., Bukowksi, R., Mekhail, T.

    Published in Journal of clinical oncology (20-06-2007)
    “…Abstract only 3525 Background: ARQ 197 is a selective inhibitor of the c-Met receptor tyrosine kinase, an oncogene implicated in tumor invasiveness,…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6

    AXENIC SEED CULTURE AND MICROPROPAGATION OF CYPRIPEDIUM REGINAE by Sokolski, K., Dovholuk, A., Dovholuk, L., Faletra, P.

    Published in Selbyana (01-01-1997)
    “…An efficient method of axenic seed propagation of large numbers of Cypripedium reginae Walt, was developed as a means of supplying seedlings for a restoration…”
    Get full text
    Journal Article